{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT04590521: Phase 4 Interventional Completed HPV Infection
(2022)
Source URL:
First approved in 2017
Source:
BLA125614
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03538327: Phase 4 Interventional Completed Hypertension
(2013)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03538327: Phase 4 Interventional Completed Hypertension
(2013)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2013)
Source URL:
First approved in 2013
Source:
505G(a)(3)
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Disinfecting Wipes by NANOFIXIT VENTURES INC.
(2020)
Source URL:
First approved in 2012
Source:
505G(a)(3)
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT01284647: Phase 4 Interventional Completed Chronic Erosive Gastritis
(2011)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Tetraprenylacetone (Geranylgeranylacetone) is an anti-peptic ulcer drug developed and approved in Japan in 1984. Tetraprenylacetone is shown to suppress H. pylori induced tissue and cell injury and inflammatory reaction, so it is expected to show beneficial effects on H. pylori-infected tissues. Tetraprenylacetone is used to treat patients suffering from peptic ulcers and gastritis. In Japan it is sold under the brand name Selbex.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2010)
Source URL:
First approved in 2009
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE
Conditions:
Farnesol, (2E,6E)- is an isoprenoid found in many aromatic plants and is also produced in humans, where it acts on numerous nuclear receptors and has received considerable attention due to its apparent anticancer properties. Farnesol is present in many essential oils such as citronella, neroli, cyclamen, lemon grass, tuberose, rose, musk, balsam, and tolu. It is used in perfumery to emphasize the odors of sweet floral perfumes. Its method of action for enhancing perfume scent is as a co-solvent that regulates the volatility of the odorants. It is especially used in lilac perfumes. Farnesol is a natural pesticide for mites and is a pheromone for several other insects. In a 1994 report released by five top cigarette companies, farnesol was listed as one of 599 additives to cigarettes. Farnesol has been suggested to function as a chemopreventative and anti-tumor agent. Farnesol is subject to restrictions on its use in perfumery as some people may become sensitized to it, however, the evidence that farnesol can cause an allergic reaction in humans is disputed.
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2009
Source:
M032
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2007)
Source URL:
First approved in 2007
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2007)
Source URL:
First approved in 2007
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE